/l. In addition to lenograstim post-transplant and lenograstim-stimulated donor bone cells (but not the donor marrow) of contaminating T cells by passing the blood stem cell leukapheresis product over marrow the first six recipients also received donor peripheral blood stem cells that had been enriched for a CD34 immune absorption column. 15 The second six study patients (cohort 2) did not receive CD34 + stem/progenitor cells and T cell depleted on an immune absorption column (cohort 1). The second six donor blood stem cells, but rather lenograstim-stimulated, T replete donor bone marrow together with lenograstim patients (cohort 2) received lenograstim post-transplant and lenograstim-stimulated donor marrow only. All 12 post-transplant. patients showed a marked elevation of their circulating white blood cell count (predominantly neutrophils) on day 1 post-transplant. Compared to carefully matched Patients and methods historical control patients the rate of neutrophil engraftment was significantly accelerated in both
Patients had acute leukaemia in first complete remission, chronic myeloid leukaemia in first chronic phase or nonpatient cohorts and platelet engraftment was accelerated in cohort 2.
Hodgkin's lymphoma and a HLA-A, -B, -DR-identical, mixed lymphocyte culture non-reactive sibling donor Keywords: G-CSF; marrow and blood cell transplants (Table 1) . Preparation for transplant was busulphan 4 mg/kg/day for 4 consecutive days followed by cyclophosphamide 60 mg/kg for 2 consecutive days. For 7 days HLA-identical sibling transplantation is an established before the bone marrow harvest the donor was given glycotreatment for a number of haematological diseases.
1,2 Over sylated recombinant human lenograstim (rHuG-CSF, lenothe past several years the procedure has become safer due grastim; AMRAD, Melbourne, Australia) 5 g/kg/day subto better control of graft-versus-host disease, 3 better prevencutaneously. On day 4 and day 5 of lenograstim tion of cytomegalovirus disease, 4 of fungal infection 5 and administration the donors for the first six patients in the of hepatic veno-occlusive disease.
6 Treatment-related morstudy (cohort 1) underwent leukapheresis of peripheral tality, however, still remains significant. 7 blood stem cells on a Cobe Spectra cell separator machine Over the past several years, autologous blood stem cell (Cobe, Sydney, Australia). Five of the six patients transplantation has been shown to be associated with faster underwent two leukaphereses and one underwent one. The engraftment of neutrophils and platelets than autologous median volume processed was 20.1 (range 13.0-27.5) litbone marrow transplantation, 8 resulting in increased safety ers. The collected blood stem cells were passed over a of the procedure. Additionally, Janssen et al 9 have shown CD34 immune absorption column (CellPro CEPRATE acceleration of neutrophil recovery after autologous bone stem cell concentration system; CellPro, Bothell, WA, marrow transplantation when lenograstim has been admin-USA). The non-absorbed cells (containing periperal blood istered before bone marrow harvest. More recently allo-T cells) were discarded while the absorbed cells containing geneic peripheral blood stem cell transplants have been the CD34 + progenitor/stem cell population were eluted and cryopreserved. The numbers of CD34 + and CD3 + (T) cells were assessed by flow cytometry. The donors of all 12 16 and infused fresh and unmanipulated (T cell These were also used for calculating survival post-transplant. Differences between groups for other parameters replete). Lenograstim 5 g/kg/day was administered to the recipient subcutaneously from the day of transplant until were assessed using a Mann-Whitney U-test. the neutrophil count reached 1.0 × 10 9 /l on 3 consecutive days.
Immune suppression to minimize the risk of graft-versusResults host disease was cyclosporin A 3 mg/kg/day until bowel function was normal, when oral cyclosporin A Blood cell numbers after leukapheresis and passage over 12.5 mg/kg/day in two divided doses was substituted, and immune absorption column (donors for cohort 1) methotrexate which was given at a dose of 7.5 mg/m 2 on days 1, 3, 6 and 11 post-transplant. Patients who were cytoThe number of nucleated cells, CD34 + cells and CD3 + cells megalovirus (CMV) seropositive or who received bone for the six donors in cohort 1 are shown in Table 3 . It marrow from a CMV seropositive donor were given gancyshould be noted that UPN 445 received no blood stem cells clovir prophylactically; 4 fluconazole 100 mg twice daily due to clotting in the column when phosphate-buffered was given from day −1 pre-transplant to day +20 post-transsaline containing calcium and magnesium was utilised in plant; cotrimoxazole one double strength tablet was given error as a wash solution. Her data are included, however, twice daily from day −8 to day −1 pre-transplant and from on an intention-to-treat basis. The decrease in number of day 21 post-transplant. Heparin 100 units/kg/day was given infused cells compared to absorbed cells was due to loss as a continuous intravenous infusion from day −8 to day during cryopreservation and subsequent thawing. +21. All patients were given a unique patient number (UPN) and were treated on protocols approved by the Bone marrow cell numbers Research Ethics Committee of St Vincent's Hospital, Sydney.
The median of nucleated cells, CD34 + cells and CD3 + cells An oral mucositis score was calculated by adding the present in the harvested bone marrow from the donors in figures produced from multiplying each grade of mucositis cohort 1 was 5.6 × 10 8 /kg, 2.5 × 10 6 /kg and 21.8 × 10 6 /kg, experienced by the number of days at that grade. respectively. The differential white cell count on the harvested bone marrow showed a marked increase in granFor each of the patients in the study, a historical control ulopoiesis with myeloblasts a median of 1 (range 1-3)%, patient was selected in whom an attempt was made to promyelocytes 3 (1-5)%, myelocytes and metamyelocytes match for diagnosis, stage of disease at the time of trans-13 (12-25)%, neutrophils and band cells 75 (63-79)%, plant, patient and donor age, donor-recipient sex match and monocytes 2 (1-4)%, eosinophils 1 (1-2)%, lymphocytes the number of post-transplant methotrexate doses adminis-3 (1-7)% and erythroblasts/100 white cells 4 (2-10)%. tered (Table 2 ). The control patients were prepared with the same busulphan/cyclophosphamide regimen as the study patients and received unstimulated T replete HLA-identical White blood count immediately post-transplant sibling marrow only. The median nucleated marrow cell dose was 2.2 (range 1.5-4.8) × 10 8 /kg. None received donor One consistent feature not seen in the control patients was an acute rise and fall in circulating blood leucocytes blood stem cells or post-transplant haematopoietic growth factor. Eleven of the 12 received prophylactic cotrimox-(primarily neutrophils) during the first several days posttransplant, reaching in one patient (UPN 458) a white count azole and five received prophylactic fluconazole.
The incidence of acute graft-versus-host disease was calof 47.3 × 10 9 /l on day 1 post-transplant (4.5 × 10 9 /l on the day of transplant) ( Figure 1) . culated using Kaplan-Meier product limit estimates. Parameters of engraftment compared to control patients and, in addition, showed a shorter number of days to an unsupported platelet count of These are shown in Table 3 . The cohort 1 study population 50 × 10 9 /l (22 vs 28, P = 0.02) and a shorter duration of had a consistently faster rate of white cell and neutrophil platelet count Ͻ20 × 10 9 /l (7 days vs 12.5 days, P = 0.03). engraftment compared to the historical matched controls.
As with the patients in cohort 1 the severity of oropharynThere was a trend towards more rapid platelet recovery, geal mucositis was significantly decreased as was the numalthough this did not reach statistical significance.
ber of days of intravenous antibiotic therapy. Because of both the initial early peak in white count
There was no significant difference between cohort 1 and immediately post-transplant and the more rapid recovery of cohort 2 for any parameter of engraftment. white cells post-transplant, the total duration of leucopenia and neutropenia was shorter in the study population than in the controls. The cohort 1 study population had a lower
Origin of engraftment number of days of fever у38.5°C in the first 30 days postSeven of the study patients differed from their donor by transplant (P = 0.005), and a lower number of days on intraeither a red cell antigen (three) or a marrow cytogenetic venous antibiotics (P = 0.04). Additionally, the number of (four) feature. Post-transplant all seven showed evidence of days during which oropharyngeal mucositis was present, donor-origin engraftment. together with the mucositis score, was lower in this group (P = 0.01 and Ͻ0.0005, respectively). This more rapid engraftment with reduction in clinical complications Graft-versus-host disease resulted in a shorter transplant hospitalisation (19 days vs 25.5 days, P Ͻ 0.0005).
The incidence of grades I-IV acute graft-versus-host disease (GVHD) was not different between the two popuThe study patients in cohort 2 showed similar findings to those in cohort 1 with faster engraftment of neutrophils lations (92% vs 87%, P = 0.4); the incidence of moderate to severe acute GVHD (grades II-IV) was zero in the study recovery after allogeneic transplantation is the use of mobilised peripheral blood stem cells. Platelet recovery population and 30% in the control population (P = 0.2, not significant).
appeared to be accelerated in several recent studies using allogeneic blood stem cells alone as the reconstituting inoculum.
10,11
Survival to day 100 post-transplant Until recently such reports have been restricted to single case studies, 22-29 usually because the donor was unsuitable This was 92% in the study population and 75% in the matched control population (P = 0.2). One patient in cohort for marrow harvesting or because the recipient had previously received and rejected a marrow allograft or had 2 of the study population died of hepatic veno-occlusive disease.
relapsed after a marrow graft. Recently, however, three small series of blood stem cell transplantation have been reported. [10] [11] [12] In each of these reports blood stem cells were used as the sole source of reconstituting stem cells and in Discussion none of them were T cells depleted from the inoculum. Most of the donors received a dose of lenograstim ranging This study showed that transplantation of lenograstimstimulated, T replete donor marrow and lenograstim adminbetween 10 g/kg/day and 16 g/kg/day. The number of CD34 + cells infused was markedly greater than in our study istration to the recipient post-transplant, with or without the addition of lenograstim mobilised, CD34
+ enriched, T cell- (Table 4) , possibly due to the lower dose of G-CSF that we administered. (We chose a dose of 5 g/kg/day because this depleted donor peripheral blood stem cells, enhanced engraftment of HLA-identical sibling bone marrow in was our first study administering G-CSF to normal donors).
Another difference was that growth factors were not utilpatients with leukemia. Neutrophil and, in cohort 2, platelet recovery was accelerated and the more rapid recovery of ised post-transplant in any of the patients from Seattle and in only two in the study by Schmitz and colleagues. neutrophils resulted in less oropharyngeal mucositis, a lower number of days with fever у38.5°C and a lesser use
Additionally the blood stem cells were infused fresh (rather than after cryopreservation) in the study by Bensinger. Platof intravenous antibiotics in the first month post-transplant. This decrease in clinical complications resulted in a elet recovery appeared accelerated in the studies by Bensinger et al and Körbling et al. Acute graft-versus-host shorter hospitalisation.
The treatment given to cohort 1 of the study group difdisease of moderate to severe intensity (grades II-IV) occurred in 3/8, 3/9 and 4/8 patients in the three studies fered in three ways from that given to the control group: cohort 1 patients received lenograstim-mobilised, CD34
+ -compared to 0/6 in cohort 1 of our own study. Indeed, in the note added in proof to the study by Körbling, the incienriched peripheral blood stem cells together with lenograstim-stimulated T replete donor marrow as well as lenograsdence of acute GVHD grades II-IV was 47%. This is of some concern, particularly if one is using the technology tim post-transplant. It would appear that the contribution of the peripheral blood stem cells was a minor one in that for patients with early stage leukaemia and is the reason we felt we needed to T cell deplete the peripheral blood cohort 2 of the study group, who received no allogeneic peripheral blood stem cells, but only lenograstim-stimuinoculum in our own series. There was a 3 log difference in the number of T cells infused between our study and lated donor bone marrow and lenograstim post-transplant, showed a similar acceleration of neutrophil recovery, and each of the other 3 studies (Table 4) . We had also wanted to preserve the important graftin addition, several parameters of platelet recovery were significantly accelerated compared to the historical conversus-leukemia effect of T replete allogeneic bone marrow transplantation. Hence we elected to retain our practice of trol population.
There are several reports of the use of lenograstim infusing donor marrow as unmanipulated and T replete. While our approach has resulted in improvement in the administration to the recipient after HLA-identical sibling bone marrow transplant to accelerate marrow recovery [19] [20] [21] short-term management of HLA-identical sibling marrow transplantation, further follow-up will be required to deterand, while all showed acceleration of neutrophil recovery post-transplant, none showed any acceleration of platelet mine the impact if any, of this approach on the leukaemia recurrence rate post-transplant. recovery. This suggests, therefore, that the lenograstimstimulated donor marrow was responsible for this. A single One important factor affecting engraftment kinetics is the graft-versus-host disease prophylactic regimen used. Those report 9 of a prospective randomised trial comparing the rates of engraftment following autologous transplantation incorporating methotrexate with cyclosporin A are likely to be associated with a slower rate of engraftment than those of peripheral blood stem cells or bone marrow harvested after lenograstim stimulation had similar (accelerated) kinutilising cyclosporin A and prednisone.
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A final interesting observation that occurred in both etics of neutrophil recovery compared to non-stimulated bone marrow, suggesting that the previously reported difcohorts of our study group and which we never witnessed in our control patients was the sharp rise in the peripheral ferences in engraftment rates between conventionally harvested autologous bone marrow and mobilised peripheral blood white cell count on the first and subsequent days post-transplant. This peak, (sometimes reaching a white cell blood stem cells reflected the activated status of the stem cells rather than the anatomical compartment from which count of almost 50 × 10 9 /l) was composed predominantly of neutrophils. Presumably the large number of myeloid they were derived. No mention was made in this study of platelet recovery.
progenitors infused in the lenograstim-stimulated marrow (with or without peripheral blood stem cells) matured To date the only reported means of accelerating platelet was responsible for this. The goal of our current study is
